A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor ...

Topical antifungals, although often effective, are being discouraged in the early treatment of seborrheic dermatitis now that ...

Zoryve is under clinical development by Arcutis Biotherapeutics and currently in Pre-Registration for Psoriasis.

Medically reviewed by Jurairat J. Molina, MD Dermatitis is a group of skin problems related to genes, environment, and ...

The rally in ARQT's stock could be attributed to the encouraging regulatory updates seeking label expansion for its sole marketed drug.

Eczema symptoms can be mild — a small patch of itchy, dry, red or pink textured skin — or they can be severe, Dr. Shasa Hu, ...

H.C. Wainwright analyst Douglas Tsao initiated coverage of Arcutis Biotherapeutics (ARQT) with a Buy rating and $19 price target The firm ...

The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This slowdown was primarily due to disappointing third-quarter earnings, reduced ...

Vulvar dermatitis is a skin condition that affects the skin of the vulva. The vulva is the external female genitalia, which includes the labia, clitoris, and vaginal opening. People with vulvar ...

Many eye ointments can help manage and treat symptoms of eye conditions like styes, pink eye, and other infections. When using eye ointments, it’s important to follow the directions. Eye ...

HealthDay News — The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older. The approval ...